SARS-CoV-2 enhances lysosomal exocytosis and deacidifies lysosomes to facilitate viral release

Abstract

The mechanism of SARS-CoV-2 egress predominantly governs the quantity and quality of progeny viruses, thereby significantly contributing to viral pathogenicity. However, the key factors influencing viral egress remain largely unclear. In this study, using transcription- and replication-competent SARS-CoV-2 virus-like-particle (SARS-CoV-2 trVLP), electron microscopy, drug inhibition assays, and cellular pH-sensitive fluorescent probes, we demonstrate that increased lysosomal exocytosis efficiency and lysosome deacidification play a pivotal role in facilitating SARS-CoV-2 egress. Specifically, SARS-CoV-2 may use multiple egress pathways, with lysosomal exocytosis as the primary mechanism and the biosynthetic secretory pathway as a less efficient route. Viral infection enhances lysosomal exocytosis via the ORF3a protein, thus facilitating viral release. SARS-CoV-2 infection also induces lysosome deacidification; moreover, treatment with bafilomycin A1, which induces lysosome deacidification, further enhances viral egress. Furthermore, we systematically investigate how viral proteins affect lysosomal pH and enzymatic activities. Our findings reveal that ORF3a and E proteins induce lysosome deacidification and diminish lysosomal enzyme activities, probably protecting progeny viruses from premature cleavage and degradation. This study provides mechanistic insight into how SARS-CoV-2 promotes lysosomal exocytosis and triggers lysosome deacidification for viral release.

Keywords

lysosomal exocytosis / lysosome deacidification / ORF3a protein / SARS-CoV-2 / synthetic biology

References

[1] Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023; 613: 130–137.

[2] El-Sadr WM, Vasan A, El-Mohandes A. Facing the new Covid-19 reality. N Engl J Med. 2023; 388: 385–387.

[3] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270–273.

[4] Oudit GY, Wang K, Viveiros A, Kellner MJ, Penninger JM. Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic. Cell. 2023; 186: 906–922.

[5] Chaouat AE, Brizic I, Kucan Brlic P, Atari N, Kliker L, Alfi O, et al. Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. iScience. 2022; 25:104935.

[6] Robinson M, Schor S, Barouch-Bentov R, Einav S. Viral journeys on the intracellular highways. Cell Mol Life Sci. 2018; 75: 3693–3714.

[7] Ravindran MS, Bagchi P, Cunningham CN, Tsai B. Opportunistic intruders: how viruses orchestrate ER functions to infect cells. Nat Rev Microbiol. 2016; 14: 407–420.

[8] Pornillos O, Garrus JE, Sundquist WI. Mechanisms of enveloped RNA virus budding. Trends Cell Biol. 2002; 12: 569–579.

[9] Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol. 2008; 82: 11318–11330.

[10] Westerbeck JW, Machamer CE. The infectious bronchitis coronavirus envelope protein alters Golgi pH to protect the spike protein and promote the release of infectious virus. J Virol. 2019; 93:e00015-19.

[11] Prydz K, Saraste J. The life cycle and enigmatic egress of coronaviruses. Mol Microbiol. 2022; 117: 1308–1316.

[12] Ghosh S, Dellibovi-Ragheb TA, Kerviel A, Pak E, Qiu Q, Fisher M, et al. β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell. 2020; 183: 1520–1535.

[13] Wang Z, He W, Li C, Chen Y, Li Z, Jiao Y, et al. The role of lysosomes as intermediates in betacoronavirus PHEV egress from nerve cells. J Virol. 2023; 97:e0133823.

[14] Mendonça L, Howe A, Gilchrist JB, Sheng Y, Sun D, Knight ML, et al. Correlative multi-scale cryo-imaging unveils SARS-CoV-2 assembly and egress. Nat Commun. 2021; 12: 4629.

[15] Eymieux S, Uzbekov R, Rouillé Y, Blanchard E, Hourioux C, Dubuisson J, et al. Secretory vesicles are the principal means of SARS-CoV-2 egress. Cells. 2021; 10: 2047.

[16] Sicari D, Chatziioannou A, Koutsandreas T, Sitia R, Chevet E. Role of the early secretory pathway in SARS-CoV-2 infection. J Cell Biol. 2020; 219:e202006005.

[17] Ju X, Zhu Y, Wang Y, Li J, Zhang J, Gong M, et al. A novel cell culture system modeling the SARS-CoV-2 life cycle. PLoS Pathog. 2021; 17:e1009439.

[18] Yu Y, Ju X, Ding Q. A nucleocapsid-based transcomplementation cell culture system of SARS-CoV-2 to recapitulate the complete viral life cycle. Bio Protoc. 2021; 11:e4257.

[19] Agola JO, Hong L, Surviladze Z, Ursu O, Waller A, Strouse JJ, et al. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. ACS Chem Biol. 2012; 7: 1095–1108.

[20] Rodríguez A, Webster P, Ortego J, Andrews NW. Lysosomes behave as Ca²⁺-regulated exocytic vesicles in fibroblasts and epithelial cells. J Cell Biol. 1997; 137: 93–104.

[21] Park R, Shen H, Liu L, Liu X, Ferguson SM, De Camilli P. Dynamin triple knockout cells reveal off target effects of commonly used dynamin inhibitors. J Cell Sci. 2013; 126: 5305–5312.

[22] Huotari J, Helenius A. Endosome maturation. EMBO J. 2011; 30: 3481–3500.

[23] Cortese M, Lee JY, Cerikan B, Neufeldt CJ, Oorschot VMJ, Köhrer S, et al. Integrative imaging reveals SARS-CoV-2-induced reshaping of subcellular morphologies. Cell Host Microbe. 2020; 28: 853–866.

[24] Tancini B, Buratta S, Delo F, Sagini K, Chiaradia E, Pellegrino RM, et al. Lysosomal exocytosis: the extracellular role of an intracellular organelle. Membranes. 2020; 10: 406.

[25] Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol. 2007; 8: 622–632.

[26] Orr ME, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer's disease. Alzheimers Res Ther. 2013; 5: 53.

[27] Bae EJ, Yang NY, Lee C, Kim S, Lee HJ, Lee SJ. Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of α-synuclein aggregates. Cell Death Dis. 2015; 6:e1901.

[28] Chen D, Zheng Q, Sun L, Ji M, Li Y, Deng H, et al. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress. Dev Cell. 2021; 56: 3250–3263.

[29] Sun X, Liu Y, Huang Z, Xu W, Hu W, Yi L, et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 2022; 29: 1240–1254.

[30] Hayn M, Hirschenberger M, Koepke L, Nchioua R, Straub JH, Klute S, et al. Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. Cell Rep. 2021; 35:109126.

[31] Mauvezin C, Neufeld TP. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy. 2015; 11: 1437–1438.

[32] Yeganeh B, Ghavami S, Kroeker AL, Mahood TH, Stelmack GL, Klonisch T, et al. Suppression of influenza A virus replication in human lung epithelial cells by noncytotoxic concentrations bafilomycin A1. Am J Physiol Lung Cell Mol Physiol. 2015; 308: L270–L286.

[33] Hou Y, Wang T, Ding Y, Yu T, Cui Y, Nie H. Expression profiles of respiratory V-ATPase and calprotectin in SARS-CoV-2 infection. Cell Death Discov. 2022; 8: 362.

[34] Lie PPY, Nixon RA. Lysosome trafficking and signaling in health and neurodegenerative diseases. Neurobiol Dis. 2019; 122: 94–105.

[35] Sanman LE, van der Linden WA, Verdoes M, Bogyo M. Bifunctional probes of cathepsin protease activity and pH reveal alterations in endolysosomal pH during bacterial infection. Cell Chem Biol. 2016; 23: 793–804.

[36] Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol. 2003; 3: 472–482.

[37] Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021; 6: 134.

[38] Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA. 2020; 117: 11727–11734.

[39] Chen DY, Chin CV, Kenney D, Tavares AH, Khan N, Conway HL, et al. Spike and nsp6 are key determinants of SARS-CoV-2 omicron BA.1 attenuation. Nature. 2023; 615: 143–150.

[40] Wang Q, Anang S, Iketani S, Guo Y, Liu L, Katsamba PS, et al. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Rep. 2022; 39:110924.

[41] Arruda HRS, Lima TM, Alvim RGF, Victorio FBA, Abreu DPB, Marsili FF, et al. Conformational stability of SARS-CoV-2 glycoprotein spike variants. iScience. 2023; 26:105696.

[42] Zhang J, Ejikemeuwa A, Gerzanich V, Nasr M, Tang Q, Simard JM, et al. Understanding the role of SARS-CoV-2 ORF3a in viral pathogenesis and COVID-19. Front Microbiol. 2022; 13:854567.

[43] Lednicky JA, Cherabuddi K, Tagliamonte MS, Elbadry MA, Subramaniam K, Waltzek TB, et al. In-frame 12-nucleotide deletion within open reading frame 3a in a SARS-CoV-2 strain isolated from a patient hospitalized with COVID-19. Microbiol Resour Announc. 2021; 10:e00137-21.

[44] Nagy Á, Pongor S, Győrffy B. Different mutations in SARS-CoV-2 associate with severe and mild outcome. Int J Antimicrob Agents. 2021; 57:106272.

[45] Hassan SS, Choudhury PP, Dayhoff GW, Aljabali AAA, Uhal BD, Lundstrom K, et al. The importance of accessory protein variants in the pathogenicity of SARS-CoV-2. Arch Biochem Biophys. 2022; 717:109124.

[46] Wang W, Qu Y, Wang X, Xiao MZX, Fu J, Chen L, et al. Genetic variety of ORF3a shapes SARS-CoV-2 fitness through modulation of lipid droplet. J Med Virol. 2023; 95:e28630.

[47] Desingu PA, Nagarajan K, Dhama K. Emergence of omicron third lineage BA.3 and its importance. J Med Virol. 2022; 94: 1808–1810.

[48] Miura K, Suzuki Y, Ishida K, Arakawa M, Wu H, Fujioka Y, et al. Distinct motifs in the E protein are required for SARS-CoV-2 virus particle formation and lysosomal deacidification in host cells. J Virol. 2023; 97:e0042623.

[49] Cabrera-Garcia D, Bekdash R, Abbott GW, Yazawa M, Harrison NL. The envelope protein of SARS-CoV-2 increases intra-Golgi pH and forms a cation channel that is regulated by pH. J Physiol. 2021; 599: 2851–2868.

[50] Xia B, Wang Y, Pan X, Cheng X, Ji H, Zuo X, et al. Why is the SARS-CoV-2 omicron variant milder? Innovation. 2022; 3: 100251.

[51] Wang WA, Carreras-Sureda A, Demaurex N. SARS-CoV-2 infection alkalinizes the ERGIC and lysosomes through the viroporin activity of the viral envelope protein. J Cell Sci. 2023; 136:jcs260685.

[52] Pearson GJ, Mears HV, Broncel M, Snijders AP, Bauer DLV, Carlton JG. ER-export and ARFRP1/AP-1-dependent delivery of SARS-CoV-2 envelope to lysosomes controls late stages of viral replication. Sci Adv. 2024; 10:eadl5012.

[53] Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022; 23: 3–20.

[54] Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, de Silva TI, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21: 162–177.

[55] Cruz-Cosme R, Zhang J, Liu D, Mahase V, Sallapalli BT, Chang P, et al. A novel diG motif in ORF3a protein of SARS-Cov-2 for intracellular transport. Front Cell Dev Biol. 2022; 10:1011221.

[56] Wang X, Lin L, Lan B, Wang Y, Du L, Chen X, et al. IGF2R-initiated proton rechanneling dictates an anti-inflammatory property in macrophages. Sci Adv. 2020; 6:eabb7389.

[57] Castaño-Rodriguez C, Honrubia JM, Gutiérrez-Álvarez J, DeDiego ML, Nieto-Torres JL, Jimenez-Guardeño JM, et al. Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis. mBio. 2018; 9:e02325-17.

[58] Kern DM, Sorum B, Mali SS, Hoel CM, Sridharan S, Remis JP, et al. Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs. Nat Struct Mol Biol. 2021; 28: 573–582.

[59] Miller AN, Houlihan PR, Matamala E, Cabezas-Bratesco D, Lee GY, Cristofori-Armstrong B, et al. The SARS-CoV-2 accessory protein Orf3a is not an ion channel, but does interact with trafficking proteins. eLife. 2023; 12:e84477.

[60] Mandala VS, McKay MJ, Shcherbakov AA, Dregni AJ, Kolocouris A, Hong M. Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol. 2020; 27: 1202–1208.

[61] Ricardo-Lax I, Luna JM, Thao TTN, Le Pen J, Yu Y, Hoffmann HH, et al. Replication and single-cycle delivery of SARS-CoV-2 replicons. Science. 2021; 374: 1099–1106.

[62] Lei C, Yang J, Hu J, Sun X. On the calculation of TCID₅₀ for quantitation of virus infectivity. Virol Sin. 2021; 36: 141–144.

[63] Qin F, Xu C, Hu J, Lei C, Zheng Z, Peng K, et al. Dissecting the cell entry pathway of baculovirus by single-particle tracking and quantitative electron microscopic analysis. J Virol. 2019; 93:JVI.00033–19.

[64] Chen M, Li W, Zhang Z, Liu S, Zhang X, Zhang XE, et al. Novel near-infrared BiFC systems from a bacterial phytochrome for imaging protein interactions and drug evaluation under physiological conditions. Biomaterials. 2015; 48: 97–107.

Rights & permissions

2026 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.